Alzheimer's Matters, the official blog of the ADDF, features insights, perspectives and commentary on current topics of interest in Alzheimer's disease and related drug discovery.

Inflammation, The Driver of Alzheimer’s Disease?


A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's disease.

Contact Sports & CTE: Are the Risks Too High?


A new study reveals a high percentage of former football players died with CTE, including 99% of NFL players tested.

Three Themes Emerge at BIO2017


Dr. Lauren Friedman details the three topics that dominated discussions at this year's BIO International Convention in San Diego.

Dementia & Alzheimer’s Disease: What’s the Difference?


Our CSO Dr. Fillit explains the differences between Alzheimer's and dementia, two terms often used interchangeably. 

Clinical Trials Inspiring Hope


Since 1998, the ADDF has invested over $100 million in the best ideas to cure Alzheimer's. We are seeing the impact of our efforts, with many promising drugs in clinical trials for Alzheimer's and more on the way.

Trial of First Broad-Spectrum Drug for Neurodegeneration Seeking Volunteers


ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a drug already FDA-approved for leukemia that is being tested as a treatment for Alzheimer’s disease.

Donor Spotlight: Joyce Cowin


Longtime supporter Joyce Cowin talks about why she has a new sense of hope about Alzheimer's treatments. She believes strongly that a victory in the fight against Alzheimer's "is inevitable and on the horizon."

Prevention: A Key to Conquering Alzheimer’s


Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials. 

Closing in on a Cure: Dr. Michela Gallagher and AGB101


Dr. Michela Gallagher of Agenebio and Johns Hopkins University is developing AGB101, which has the potential to prevent mild cognitive impairment from progressing to Alzheimer's disease.

Does Verubecestat Signal the End of the Amyloid Hypothesis?


Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.